DK2909182T3 - Fremstilling af og formulering omfattende en mek-inhibitor - Google Patents
Fremstilling af og formulering omfattende en mek-inhibitor Download PDFInfo
- Publication number
- DK2909182T3 DK2909182T3 DK13847106.5T DK13847106T DK2909182T3 DK 2909182 T3 DK2909182 T3 DK 2909182T3 DK 13847106 T DK13847106 T DK 13847106T DK 2909182 T3 DK2909182 T3 DK 2909182T3
- Authority
- DK
- Denmark
- Prior art keywords
- preparation
- mek inhibitor
- formulation including
- formulation
- mek
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/08—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Metallurgy (AREA)
- Materials Engineering (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261716169P | 2012-10-19 | 2012-10-19 | |
| PCT/US2013/065633 WO2014063024A1 (en) | 2012-10-19 | 2013-10-18 | Preparation of and formulation comprising a mek inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2909182T3 true DK2909182T3 (da) | 2020-02-17 |
Family
ID=50488781
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13847106.5T DK2909182T3 (da) | 2012-10-19 | 2013-10-18 | Fremstilling af og formulering omfattende en mek-inhibitor |
| DK19211405.6T DK3702351T3 (da) | 2012-10-19 | 2013-10-18 | Formulering omfattende en mek-inhibitor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19211405.6T DK3702351T3 (da) | 2012-10-19 | 2013-10-18 | Formulering omfattende en mek-inhibitor |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US9238627B2 (https=) |
| EP (3) | EP4306171A3 (https=) |
| JP (3) | JP6385939B2 (https=) |
| CN (3) | CN109336824B (https=) |
| AR (1) | AR099630A1 (https=) |
| BR (1) | BR112015008623B1 (https=) |
| CA (2) | CA3079071C (https=) |
| CY (1) | CY1122670T1 (https=) |
| DK (2) | DK2909182T3 (https=) |
| ES (2) | ES2971077T3 (https=) |
| FI (1) | FI3702351T3 (https=) |
| HR (1) | HRP20240033T1 (https=) |
| HU (2) | HUE065433T2 (https=) |
| JO (1) | JOP20130304B1 (https=) |
| LT (1) | LT3702351T (https=) |
| PL (2) | PL3702351T3 (https=) |
| PT (2) | PT3702351T (https=) |
| RS (1) | RS65117B1 (https=) |
| RU (2) | RU2018127873A (https=) |
| SI (2) | SI3702351T1 (https=) |
| SM (1) | SMT202400044T1 (https=) |
| TW (1) | TWI650316B (https=) |
| WO (1) | WO2014063024A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR099630A1 (es) | 2012-10-19 | 2016-08-10 | Novartis Ag | Preparación de un inhibidor de mek y formulación que lo comprende |
| CN105566225A (zh) * | 2015-02-16 | 2016-05-11 | 苏州晶云药物科技有限公司 | 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法 |
| MX387795B (es) * | 2016-06-03 | 2025-03-19 | Array Biopharma Inc | Combinaciones farmaceuticas. |
| CN111646946A (zh) * | 2017-11-14 | 2020-09-11 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的苯并咪唑化合物及包含该化合物的组合物 |
| TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| WO2019139970A1 (en) * | 2018-01-09 | 2019-07-18 | Duke University | Topical administration of mek inhibiting agents for the treatment of skin disorders |
| WO2020212832A1 (en) * | 2019-04-16 | 2020-10-22 | Alembic Pharmaceuticals Limited | Process of preparation of benzimidazole compounds |
| WO2021116901A1 (en) * | 2019-12-09 | 2021-06-17 | Biocon Limited | Forms of binimetinib and process for preparation thereof |
| AU2021358394A1 (en) | 2020-10-05 | 2023-04-13 | Pierre Fabre Medicament | Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma |
| CN112679438A (zh) * | 2020-12-31 | 2021-04-20 | 武汉九州钰民医药科技有限公司 | 制备司美替尼的方法 |
| EP4346826A4 (en) | 2021-05-27 | 2025-04-30 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES |
| WO2023084489A1 (en) | 2021-11-15 | 2023-05-19 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
| EP4460303A4 (en) * | 2022-01-06 | 2025-07-23 | Msn Laboratories Private Ltd R&D Center | IMPROVED PROCESS FOR THE PREPARATION OF 5-[(4-BROMO-2-FLUOROPHENYL)AMINO]-4-FLUORO-N-(2HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE |
| WO2024003942A1 (en) * | 2022-07-01 | 2024-01-04 | Natco Pharma Limited | An improved process for the preparation of selumetinib sulfate |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| FR3159741A1 (fr) | 2024-03-04 | 2025-09-05 | Pierre Fabre Medicament | Formulation topique comprenant du binimetinib |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2355470C (en) * | 1999-01-13 | 2008-09-30 | Warner-Lambert Company | Benzoheterocycles and their use as mek inhibitors |
| CA2377092A1 (en) * | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| SG2013013339A (en) * | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| CA2532067C (en) * | 2003-07-24 | 2010-12-21 | Stephen Douglas Barrett | N-methyle-substituted benzamidazoles |
| AU2005283422C1 (en) | 2004-09-17 | 2017-02-02 | Eisai R & D Management Co., Ltd. | Medicinal composition |
| US8039637B2 (en) | 2005-06-23 | 2011-10-18 | Array Biopharma Inc. | Process for preparing benzimidazole compounds |
| EP1904061B1 (en) | 2005-06-23 | 2018-12-26 | Array Biopharma, Inc. | SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS |
| WO2009018233A1 (en) * | 2007-07-30 | 2009-02-05 | Ardea Biosciences, Inc. | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
| TWI405756B (zh) * | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
| EP1966155A1 (en) * | 2005-12-21 | 2008-09-10 | AstraZeneca AB | Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer |
| WO2009064675A1 (en) | 2007-11-12 | 2009-05-22 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| BRPI0925050A2 (pt) * | 2009-04-21 | 2015-08-04 | Novartis Ag | Compostos heterocíclicos como inibidores de mek |
| WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
| JP2014528928A (ja) | 2011-09-01 | 2014-10-30 | ノバルティス アーゲー | ヌーナン症候群の治療のための有機化合物の使用 |
| AR099630A1 (es) | 2012-10-19 | 2016-08-10 | Novartis Ag | Preparación de un inhibidor de mek y formulación que lo comprende |
-
2013
- 2013-10-18 AR ARP130103796A patent/AR099630A1/es not_active Application Discontinuation
- 2013-10-18 PL PL19211405.6T patent/PL3702351T3/pl unknown
- 2013-10-18 DK DK13847106.5T patent/DK2909182T3/da active
- 2013-10-18 ES ES19211405T patent/ES2971077T3/es active Active
- 2013-10-18 HU HUE19211405A patent/HUE065433T2/hu unknown
- 2013-10-18 FI FIEP19211405.6T patent/FI3702351T3/fi active
- 2013-10-18 RS RS20240112A patent/RS65117B1/sr unknown
- 2013-10-18 BR BR112015008623-3A patent/BR112015008623B1/pt active IP Right Grant
- 2013-10-18 PT PT192114056T patent/PT3702351T/pt unknown
- 2013-10-18 PL PL13847106T patent/PL2909182T3/pl unknown
- 2013-10-18 SI SI201332074T patent/SI3702351T1/sl unknown
- 2013-10-18 SM SM20240044T patent/SMT202400044T1/it unknown
- 2013-10-18 RU RU2018127873A patent/RU2018127873A/ru not_active Application Discontinuation
- 2013-10-18 EP EP23211278.9A patent/EP4306171A3/en active Pending
- 2013-10-18 PT PT138471065T patent/PT2909182T/pt unknown
- 2013-10-18 CN CN201811124073.6A patent/CN109336824B/zh active Active
- 2013-10-18 CN CN201810684986.7A patent/CN109456272A/zh active Pending
- 2013-10-18 US US14/057,498 patent/US9238627B2/en active Active
- 2013-10-18 ES ES13847106T patent/ES2772498T3/es active Active
- 2013-10-18 CN CN201380063271.5A patent/CN104870427B/zh active Active
- 2013-10-18 WO PCT/US2013/065633 patent/WO2014063024A1/en not_active Ceased
- 2013-10-18 EP EP19211405.6A patent/EP3702351B1/en active Active
- 2013-10-18 JP JP2015538050A patent/JP6385939B2/ja active Active
- 2013-10-18 HU HUE13847106A patent/HUE047708T2/hu unknown
- 2013-10-18 LT LTEP19211405.6T patent/LT3702351T/lt unknown
- 2013-10-18 DK DK19211405.6T patent/DK3702351T3/da active
- 2013-10-18 SI SI201331672T patent/SI2909182T1/sl unknown
- 2013-10-18 TW TW102137813A patent/TWI650316B/zh active
- 2013-10-18 HR HRP20240033TT patent/HRP20240033T1/hr unknown
- 2013-10-18 CA CA3079071A patent/CA3079071C/en active Active
- 2013-10-18 CA CA2888474A patent/CA2888474C/en active Active
- 2013-10-18 RU RU2015118572A patent/RU2669391C2/ru active
- 2013-10-18 EP EP13847106.5A patent/EP2909182B1/en active Active
- 2013-10-20 JO JOP/2013/0304A patent/JOP20130304B1/ar active
-
2015
- 2015-12-18 US US14/974,655 patent/US9562016B2/en active Active
- 2015-12-18 US US14/974,588 patent/US9382212B1/en active Active
-
2016
- 2016-02-25 US US15/053,441 patent/US9598376B2/en active Active
-
2017
- 2017-02-28 US US15/445,393 patent/US9980944B2/en active Active
- 2017-12-14 US US15/842,715 patent/US10398683B2/en active Active
-
2018
- 2018-06-07 JP JP2018109486A patent/JP6737838B2/ja active Active
-
2019
- 2019-07-16 US US16/512,823 patent/US10729678B2/en active Active
- 2019-08-19 JP JP2019149828A patent/JP2019194272A/ja active Pending
-
2020
- 2020-02-18 CY CY20201100148T patent/CY1122670T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2909182T3 (da) | Fremstilling af og formulering omfattende en mek-inhibitor | |
| IL269045A (en) | Aptamers and uses thereof | |
| DK2903600T3 (da) | Virusholdig formulering og anvendelse deraf | |
| DK3608325T3 (da) | Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse | |
| DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
| PL3364651T3 (pl) | Wyświetlacze projekcyjne o dużej luminancji i powiązane sposoby | |
| DK2609956T3 (da) | Midlertidigt foldbart kateteraggregat og dertil hørende fremgangsmåde | |
| DK2920149T3 (da) | 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf | |
| BR112015003153A2 (pt) | baricitinib deuterado | |
| EP2539521C0 (en) | Scaffolding | |
| DK2933685T3 (da) | Procespatron og billeddannelsesindretning | |
| BR112014011282A2 (pt) | dispositivo escravo e rede | |
| DK3392252T3 (da) | Pyrimido-pyridazinonforbindelser og deres anvendelse | |
| DK2917181T3 (da) | Heteroarylderivater og anvendelser deraf | |
| CO6870048A2 (es) | Formulación herbicida mejorada | |
| DK3326642T3 (da) | Langtidsvirkende koagulationsfaktorer og brugen deraf | |
| BR112014000015A2 (pt) | formulação | |
| DK2704744T3 (da) | Komplementfaktor-b-analoger og anvendelser deraf | |
| EP2850086A4 (en) | HETEROARYLCYANINFARBSTOFFE | |
| SMT201700046B (it) | Micobatterio ricombinante come vaccino | |
| CL2015000638A1 (es) | Composiciones herbicidas que contienen aminopiralid y triclopir | |
| DK2943460T3 (da) | 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf | |
| BR112015007217A2 (pt) | compostos e usos do composto | |
| DK2849798T3 (da) | Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder | |
| EP2878228A4 (en) | EASEL |